Cargando…

Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region

Previous studies investigated the efficacy and the safety of bendamustine (B) vs. chlorambucil (Chl) associated with rituximab (R) in fludarabine-ineligible patients with treated and untreated chronic lymphocytic leukemia (CLL). We conducted a retrospective multicenter study in the Lazio region to f...

Descripción completa

Detalles Bibliográficos
Autores principales: Autore, Francesco, Innocenti, Idanna, Corrente, Francesco, Del Principe, Maria Ilaria, Rosati, Serena, Falcucci, Paolo, Fresa, Alberto, Conte, Esmeralda, Limongiello, Maria Assunta, Renzi, Daniela, De Padua, Laura, Andriani, Alessandro, Pisani, Francesco, Cimino, Giuseppe, Tafuri, Agostino, Montanaro, Marco, Mauro, Francesca Romana, Del Poeta, Giovanni, Laurenti, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298101/
https://www.ncbi.nlm.nih.gov/pubmed/32587827
http://dx.doi.org/10.3389/fonc.2020.00848
_version_ 1783547144482848768
author Autore, Francesco
Innocenti, Idanna
Corrente, Francesco
Del Principe, Maria Ilaria
Rosati, Serena
Falcucci, Paolo
Fresa, Alberto
Conte, Esmeralda
Limongiello, Maria Assunta
Renzi, Daniela
De Padua, Laura
Andriani, Alessandro
Pisani, Francesco
Cimino, Giuseppe
Tafuri, Agostino
Montanaro, Marco
Mauro, Francesca Romana
Del Poeta, Giovanni
Laurenti, Luca
author_facet Autore, Francesco
Innocenti, Idanna
Corrente, Francesco
Del Principe, Maria Ilaria
Rosati, Serena
Falcucci, Paolo
Fresa, Alberto
Conte, Esmeralda
Limongiello, Maria Assunta
Renzi, Daniela
De Padua, Laura
Andriani, Alessandro
Pisani, Francesco
Cimino, Giuseppe
Tafuri, Agostino
Montanaro, Marco
Mauro, Francesca Romana
Del Poeta, Giovanni
Laurenti, Luca
author_sort Autore, Francesco
collection PubMed
description Previous studies investigated the efficacy and the safety of bendamustine (B) vs. chlorambucil (Chl) associated with rituximab (R) in fludarabine-ineligible patients with treated and untreated chronic lymphocytic leukemia (CLL). We conducted a retrospective multicenter study in the Lazio region to further evaluate and compare the efficacy and the toxicity of Chl-R and B-R regimen in CLL patients over the age of 65. We enrolled 192 untreated CLL patients: 111 treated with B-R and 81 with Chl-R. The overall response rates (ORR; 93.6% in B-R and 86.5% in Chl-R) were not statistically different between the two groups, such as progression-free survival (PFS), time to retreatment (TTR), and overall survival (OS). The B-R group showed a higher hematological (p = 0.007) and extra-hematological (p = 0.008) toxicity. When comparing the toxicities according to age, we noted that the extra-hematological toxicity was higher in patients over the age of 75 who were treated with B-R than those treated with Chl-R (p = 0.03). This retrospective study confirms the feasibility of B-R and Chl-R in elderly untreated CLL patients. Currently, patients who are over 75 and unfit are usually treated with Chl-R. This scheme allows achieving the same ORR, PFS, TTR, and OS when compared with B-R because of hematological and extra-hematological toxicities due to B, in which a greater dose reduction has been shown in comparison to Chl.
format Online
Article
Text
id pubmed-7298101
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-72981012020-06-24 Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region Autore, Francesco Innocenti, Idanna Corrente, Francesco Del Principe, Maria Ilaria Rosati, Serena Falcucci, Paolo Fresa, Alberto Conte, Esmeralda Limongiello, Maria Assunta Renzi, Daniela De Padua, Laura Andriani, Alessandro Pisani, Francesco Cimino, Giuseppe Tafuri, Agostino Montanaro, Marco Mauro, Francesca Romana Del Poeta, Giovanni Laurenti, Luca Front Oncol Oncology Previous studies investigated the efficacy and the safety of bendamustine (B) vs. chlorambucil (Chl) associated with rituximab (R) in fludarabine-ineligible patients with treated and untreated chronic lymphocytic leukemia (CLL). We conducted a retrospective multicenter study in the Lazio region to further evaluate and compare the efficacy and the toxicity of Chl-R and B-R regimen in CLL patients over the age of 65. We enrolled 192 untreated CLL patients: 111 treated with B-R and 81 with Chl-R. The overall response rates (ORR; 93.6% in B-R and 86.5% in Chl-R) were not statistically different between the two groups, such as progression-free survival (PFS), time to retreatment (TTR), and overall survival (OS). The B-R group showed a higher hematological (p = 0.007) and extra-hematological (p = 0.008) toxicity. When comparing the toxicities according to age, we noted that the extra-hematological toxicity was higher in patients over the age of 75 who were treated with B-R than those treated with Chl-R (p = 0.03). This retrospective study confirms the feasibility of B-R and Chl-R in elderly untreated CLL patients. Currently, patients who are over 75 and unfit are usually treated with Chl-R. This scheme allows achieving the same ORR, PFS, TTR, and OS when compared with B-R because of hematological and extra-hematological toxicities due to B, in which a greater dose reduction has been shown in comparison to Chl. Frontiers Media S.A. 2020-06-10 /pmc/articles/PMC7298101/ /pubmed/32587827 http://dx.doi.org/10.3389/fonc.2020.00848 Text en Copyright © 2020 Autore, Innocenti, Corrente, Del Principe, Rosati, Falcucci, Fresa, Conte, Limongiello, Renzi, De Padua, Andriani, Pisani, Cimino, Tafuri, Montanaro, Mauro, Del Poeta and Laurenti. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Autore, Francesco
Innocenti, Idanna
Corrente, Francesco
Del Principe, Maria Ilaria
Rosati, Serena
Falcucci, Paolo
Fresa, Alberto
Conte, Esmeralda
Limongiello, Maria Assunta
Renzi, Daniela
De Padua, Laura
Andriani, Alessandro
Pisani, Francesco
Cimino, Giuseppe
Tafuri, Agostino
Montanaro, Marco
Mauro, Francesca Romana
Del Poeta, Giovanni
Laurenti, Luca
Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region
title Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region
title_full Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region
title_fullStr Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region
title_full_unstemmed Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region
title_short Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region
title_sort front-line therapy for elderly chronic lymphocytic leukemia patients: bendamustine plus rituximab or chlorambucil plus rituximab? real-life retrospective multicenter study in the lazio region
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298101/
https://www.ncbi.nlm.nih.gov/pubmed/32587827
http://dx.doi.org/10.3389/fonc.2020.00848
work_keys_str_mv AT autorefrancesco frontlinetherapyforelderlychroniclymphocyticleukemiapatientsbendamustineplusrituximaborchlorambucilplusrituximabrealliferetrospectivemulticenterstudyinthelazioregion
AT innocentiidanna frontlinetherapyforelderlychroniclymphocyticleukemiapatientsbendamustineplusrituximaborchlorambucilplusrituximabrealliferetrospectivemulticenterstudyinthelazioregion
AT correntefrancesco frontlinetherapyforelderlychroniclymphocyticleukemiapatientsbendamustineplusrituximaborchlorambucilplusrituximabrealliferetrospectivemulticenterstudyinthelazioregion
AT delprincipemariailaria frontlinetherapyforelderlychroniclymphocyticleukemiapatientsbendamustineplusrituximaborchlorambucilplusrituximabrealliferetrospectivemulticenterstudyinthelazioregion
AT rosatiserena frontlinetherapyforelderlychroniclymphocyticleukemiapatientsbendamustineplusrituximaborchlorambucilplusrituximabrealliferetrospectivemulticenterstudyinthelazioregion
AT falcuccipaolo frontlinetherapyforelderlychroniclymphocyticleukemiapatientsbendamustineplusrituximaborchlorambucilplusrituximabrealliferetrospectivemulticenterstudyinthelazioregion
AT fresaalberto frontlinetherapyforelderlychroniclymphocyticleukemiapatientsbendamustineplusrituximaborchlorambucilplusrituximabrealliferetrospectivemulticenterstudyinthelazioregion
AT conteesmeralda frontlinetherapyforelderlychroniclymphocyticleukemiapatientsbendamustineplusrituximaborchlorambucilplusrituximabrealliferetrospectivemulticenterstudyinthelazioregion
AT limongiellomariaassunta frontlinetherapyforelderlychroniclymphocyticleukemiapatientsbendamustineplusrituximaborchlorambucilplusrituximabrealliferetrospectivemulticenterstudyinthelazioregion
AT renzidaniela frontlinetherapyforelderlychroniclymphocyticleukemiapatientsbendamustineplusrituximaborchlorambucilplusrituximabrealliferetrospectivemulticenterstudyinthelazioregion
AT depadualaura frontlinetherapyforelderlychroniclymphocyticleukemiapatientsbendamustineplusrituximaborchlorambucilplusrituximabrealliferetrospectivemulticenterstudyinthelazioregion
AT andrianialessandro frontlinetherapyforelderlychroniclymphocyticleukemiapatientsbendamustineplusrituximaborchlorambucilplusrituximabrealliferetrospectivemulticenterstudyinthelazioregion
AT pisanifrancesco frontlinetherapyforelderlychroniclymphocyticleukemiapatientsbendamustineplusrituximaborchlorambucilplusrituximabrealliferetrospectivemulticenterstudyinthelazioregion
AT ciminogiuseppe frontlinetherapyforelderlychroniclymphocyticleukemiapatientsbendamustineplusrituximaborchlorambucilplusrituximabrealliferetrospectivemulticenterstudyinthelazioregion
AT tafuriagostino frontlinetherapyforelderlychroniclymphocyticleukemiapatientsbendamustineplusrituximaborchlorambucilplusrituximabrealliferetrospectivemulticenterstudyinthelazioregion
AT montanaromarco frontlinetherapyforelderlychroniclymphocyticleukemiapatientsbendamustineplusrituximaborchlorambucilplusrituximabrealliferetrospectivemulticenterstudyinthelazioregion
AT maurofrancescaromana frontlinetherapyforelderlychroniclymphocyticleukemiapatientsbendamustineplusrituximaborchlorambucilplusrituximabrealliferetrospectivemulticenterstudyinthelazioregion
AT delpoetagiovanni frontlinetherapyforelderlychroniclymphocyticleukemiapatientsbendamustineplusrituximaborchlorambucilplusrituximabrealliferetrospectivemulticenterstudyinthelazioregion
AT laurentiluca frontlinetherapyforelderlychroniclymphocyticleukemiapatientsbendamustineplusrituximaborchlorambucilplusrituximabrealliferetrospectivemulticenterstudyinthelazioregion